Medical sterilization company Sterilis said yesterday it tapped former Nanosphere (NSDQ:NSPH) chief exec Michael McGarrity as its new CEO. McGarrity held the CEO position at Nanosphere from February 2013 to last June when he oversaw the company’s $76.9 million acquisition by Luminex (NSDQ:LMNX). Prior to his time as head of Nanosphere, McGarrity held positions in sales, marketing […]
Luminex (NSDQ:LMNX) said today that it closed its buy of Nanosphere (NSDQ:NSPH) through the purchase of 45.3 million shares at $1.70 per share, offering up $76.9 million for the company. The company said that in addition to the purchased shares, it sent notices of guaranteed deliver with respect to 953,173 shares, and that the merger was completed […]
Luminex (NSDQ:LMNX) said today that a 3rd-party offer for Nanosphere (NSDQ:NSPH) prompted it to raise its own $83 million bid for the company and its Verigene molecular diagnostics technology. Last week Luminex offered $1.35 pe share for Nanosphere and said it would also pay off some $25 million of Nanosphere’s debt. Today the company said a $1.50-per-share bid from an […]
Luminex (NSDQ:LMNX) agreed to pay a total of $83 million to acquire Nanosphere (NSDQ:NSPH) and its Verigene molecular diagnostics technology. The $1.35-per-share, all-cash deal consists of a 15-day tender offer for NSPH shares by Luminex, followed by a merger to buy up and untendered shares, the companies said. It’s expected to close during the 2nd quarter, they […]
JenaValve said this week that it tapped Victoria Carr-Brendel, former general manager of Boston Scientific‘s (NYSE:BSX) Bayer Interventional business, as its new chief executive officer. Carr-Brendel will replace Jan Keltjens, who served as interim CEO of the transcatheter aortic valve repair-focused company since January 2015. Keltjens will remain with the company as chairman of the board, JenaValve said. […]
A year after closing on a $30 million offering, Nanosphere said yesterday that it’s hired an investment bank to examine the proverbial "strategic alternatives," including a possible sale of the molecular diagnostics technology business.